IN2013MU02611A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02611A
IN2013MU02611A IN2611MU2013A IN2013MU02611A IN 2013MU02611 A IN2013MU02611 A IN 2013MU02611A IN 2611MU2013 A IN2611MU2013 A IN 2611MU2013A IN 2013MU02611 A IN2013MU02611 A IN 2013MU02611A
Authority
IN
India
Prior art keywords
compounds
diseases
inhibitors
janus kinase
present
Prior art date
Application number
Other languages
English (en)
Inventor
Ranjit C Desai
Jigar Desai
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES14793899.7T priority Critical patent/ES2618072T3/es
Priority to EP14793899.7A priority patent/EP3030561B1/en
Priority to HUE14793899A priority patent/HUE033448T2/en
Priority to KR1020167005187A priority patent/KR101665301B1/ko
Priority to IN2611MU2013 priority patent/IN2013MU02611A/en
Priority to CN201480054915.9A priority patent/CN105612154A/zh
Priority to DK14793899.7T priority patent/DK3030561T3/en
Priority to US14/910,028 priority patent/US9556148B2/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to PCT/IN2014/000515 priority patent/WO2015019365A1/en
Priority to PT147938997T priority patent/PT3030561T/pt
Priority to JP2016517296A priority patent/JP2016525071A/ja
Priority to PL14793899T priority patent/PL3030561T3/pl
Priority to TW103126910A priority patent/TWI562990B/zh
Priority to ARP140102982A priority patent/AR097282A1/es
Publication of IN2013MU02611A publication Critical patent/IN2013MU02611A/en
Priority to HK16110100.8A priority patent/HK1222386A1/zh
Priority to HRP20170277TT priority patent/HRP20170277T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2611MU2013 2013-08-07 2014-08-06 IN2013MU02611A (ar)

Priority Applications (16)

Application Number Priority Date Filing Date Title
PCT/IN2014/000515 WO2015019365A1 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
EP14793899.7A EP3030561B1 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
PT147938997T PT3030561T (pt) 2013-08-07 2014-08-06 N-cianometilamidas como inibidores de cinase janus
IN2611MU2013 IN2013MU02611A (ar) 2013-08-07 2014-08-06
CN201480054915.9A CN105612154A (zh) 2013-08-07 2014-08-06 作为詹纳斯激酶的抑制剂的n-氰基甲基酰胺
DK14793899.7T DK3030561T3 (en) 2013-08-07 2014-08-06 N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE
US14/910,028 US9556148B2 (en) 2013-08-07 2014-08-06 N-cyanomethylamides as inhibitors of janus kinase
ES14793899.7T ES2618072T3 (es) 2013-08-07 2014-08-06 N-Cianometilamidas como inhibidores de la quinasa Janus
HUE14793899A HUE033448T2 (en) 2013-08-07 2014-08-06 Janus kinase inhibitor N-cyanomethylamides
KR1020167005187A KR101665301B1 (ko) 2013-08-07 2014-08-06 야누스 키나제의 억제제로서 n-시아노메틸아미드
JP2016517296A JP2016525071A (ja) 2013-08-07 2014-08-06 ヤーヌスキナーゼのインヒビターとしてのｎ−シアノメチルアミド
PL14793899T PL3030561T3 (pl) 2013-08-07 2014-08-06 N-cyjanometyloamidy jako inhibitory kinaz janusowych
TW103126910A TWI562990B (en) 2013-08-07 2014-08-06 Novel compounds as inhibitors of janus kinase
ARP140102982A AR097282A1 (es) 2013-08-07 2014-08-07 Compuestos como inhibidores de la janus quinasa
HK16110100.8A HK1222386A1 (zh) 2013-08-07 2016-08-24 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺
HRP20170277TT HRP20170277T1 (hr) 2013-08-07 2017-02-21 N-cijanometilamidi kao inhibitori janus kinaze

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2611MU2013 IN2013MU02611A (ar) 2013-08-07 2014-08-06

Publications (1)

Publication Number Publication Date
IN2013MU02611A true IN2013MU02611A (ar) 2015-06-12

Family

ID=54199342

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2611MU2013 IN2013MU02611A (ar) 2013-08-07 2014-08-06

Country Status (16)

Country Link
US (1) US9556148B2 (ar)
EP (1) EP3030561B1 (ar)
JP (1) JP2016525071A (ar)
KR (1) KR101665301B1 (ar)
CN (1) CN105612154A (ar)
AR (1) AR097282A1 (ar)
DK (1) DK3030561T3 (ar)
ES (1) ES2618072T3 (ar)
HK (1) HK1222386A1 (ar)
HR (1) HRP20170277T1 (ar)
HU (1) HUE033448T2 (ar)
IN (1) IN2013MU02611A (ar)
PL (1) PL3030561T3 (ar)
PT (1) PT3030561T (ar)
TW (1) TWI562990B (ar)
WO (1) WO2015019365A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801910A (zh) * 2016-06-01 2016-07-27 扬州兰都塑料科技有限公司 一种电力电缆阻燃助剂
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1286302B1 (it) 1996-04-10 1998-07-08 Rotta Research Lab Chinazoline-4-amino-2-(piperidino-1-il-4-sostituite) ad attivita' anti-ipertensiva, procedimento per la loro preparazione e loro uso
DK1188747T3 (da) 1999-05-24 2006-01-23 Mitsubishi Pharma Corp Phenoxypropylaminforbindelser
GB0012240D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
EP1343756A2 (en) 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
TW200407127A (en) 2002-08-21 2004-05-16 Astrazeneca Ab Chemical compounds
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
ITMI20040954A1 (it) 2004-05-12 2004-08-12 Univ Degli Studi Milano Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
ES2427136T3 (es) 2004-06-21 2013-10-29 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
JP4624315B2 (ja) 2005-12-20 2011-02-02 株式会社リヒトラブ 綴じ具
WO2007089768A2 (en) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
JP2010510224A (ja) 2006-11-17 2010-04-02 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのアミノピロリジン類
MX2009009792A (es) * 2007-03-12 2009-09-23 Cytopia Res Pty Ltd Compuestos de fenil amino pirimidina y usos de los mismos.
CA2689989A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
ATE516276T1 (de) 2007-09-19 2011-07-15 Albemarle Corp Verfahren zur herstellung von 1,2,4-triazol-3-one
US7982036B2 (en) 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009103032A1 (en) * 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
JP5705720B2 (ja) 2008-04-16 2015-04-22 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
KR101773313B1 (ko) 2008-04-16 2017-08-31 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010039518A2 (en) 2008-09-23 2010-04-08 Rigel Pharmaceuticals, Inc. Tricyclic carbamate jak inhibitors
US8268851B2 (en) 2008-12-23 2012-09-18 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5815411B2 (ja) 2008-12-30 2015-11-17 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジンジアミンキナーゼ阻害剤
ES2473584T3 (es) 2009-01-23 2014-07-07 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
US8765763B2 (en) 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
US20110028503A1 (en) 2009-07-28 2011-02-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DE102010003599A1 (de) 2010-04-01 2011-10-06 Lisa Dräxlmaier GmbH Verfahren zur Kabelkonfektionierung sowie konfektioniertes Kabel
WO2013010453A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Chemoking receptor antagonists
WO2013093940A1 (en) 2011-12-20 2013-06-27 Council Of Scientific & Industrial Research Nitrofurfuryl substituted phenyl linked piperidino-oxadiazoline conjugates as anti-tubercular agents and process for the preparation thereof
WO2013139717A1 (en) 2012-03-19 2013-09-26 Smardtv S.A. A cicam system for processing multiple programme transport streams

Also Published As

Publication number Publication date
EP3030561B1 (en) 2017-01-11
HK1222386A1 (zh) 2017-06-30
DK3030561T3 (en) 2017-03-27
PL3030561T3 (pl) 2017-08-31
KR101665301B1 (ko) 2016-10-11
CN105612154A (zh) 2016-05-25
AR097282A1 (es) 2016-03-02
EP3030561A1 (en) 2016-06-15
US9556148B2 (en) 2017-01-31
HUE033448T2 (en) 2017-11-28
TW201518290A (zh) 2015-05-16
WO2015019365A8 (en) 2016-02-18
KR20160030580A (ko) 2016-03-18
TWI562990B (en) 2016-12-21
JP2016525071A (ja) 2016-08-22
HRP20170277T1 (hr) 2017-05-19
ES2618072T3 (es) 2017-06-20
WO2015019365A1 (en) 2015-02-12
PT3030561T (pt) 2017-03-23
US20160176849A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12020500195A1 (en) Pyrimidinones as factor xia inhibitors
PH12014502615B1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
MY155639A (en) 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
MX2013004298A (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
GEP20227344B (en) Pyrimidine compound as jak kinase inhibitor
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
PH12014502538A1 (en) Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods tehreof
NZ725001A (en) Tricyclic compound and jak inhibitor
IN2013MU02611A (ar)
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
MY192305A (en) Bipyrazole derivatives as jak inhibitors
TN2010000471A1 (en) 2-6 diamino pyrimidin 5-yl carboxamides as syk or jak kinases inhibitors
TH131403B (th) สารประกอบไพริมิดีนชนิดใหม่ ดังสารยับยั้ง mTOR และ PI3K